Treatment of Hypertension in Patients With Coronary Artery Disease A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension Clive Rosendorff, MD, PhD, DScMed, FAHA, FACC, FASH, Chair; Daniel T. Lackland, DrPH, FAHA, FASH, Co-Chair; Matthew Allison, MD, FAHA; Wilbert S. Aronow, MD, FAHA, FACC; Henry R. Black, MD, FAHA, FASH; Roger S. Blumenthal, MD, FAHA, FACC; Christopher P. Cannon, MD, FAHA, FACC; James A. de Lemos, MD, FAHA, FACC; William J. Elliott, MD, PhD, FASH; Laura Findeiss, MD, FAHA; Bernard J. Gersh, MB ChB, DPhil, FAHA, MACC; Joel M. Gore, MD, FAHA, FACC; Daniel Levy, MD, FACC; Janet B. Long, MSN, FAHA; Christopher M. O Connor, MD, FACC; Patrick T. O Gara, MD, FAHA, FACC; Gbenga Ogedegbe, MD, MPH, FASH; Suzanne Oparil, MD, FAHA, FACC, FASH; William B. White, MD, FAHA, FASH; on behalf of the American Heart Association, American College of Cardiology, and American Society of Hypertension AHA/ACC/ASH Scientific Statement Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYP.0000000000000018 Table of Contents 1. Relationship Between Hypertension and CAD 1374 1.1. Epidemiology of Hypertension and CAD 1374 1.1.1. Effects of Treatment 1374 1.1.2. Risk Factor Interactions 1376 1.1.3. Risk Factor Reduction 1376 1.1.4. Dyslipidemia 1376 1.1.5. Diabetes Mellitus 1377 1.1.6. Smoking 1377 1.1.7. Obesity 1377 1.1.8. Peripheral Artery Disease 1377 1.1.9. Chronic Kidney Disease 1378 1.2. Mechanisms of Hypertension and CAD 1378 1.2.1. Genetics 1378 1.2.2. Physical Forces and Hemodynamics 1378 1.2.3. Endothelial Dysfunction 1379 1.2.4. Oxidative Stress 1379 1.2.5. Humoral and Metabolic Factors 1379 1.2.6. 